Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the “Company”), the world leader in the application of gene editing technologies, today announces that it has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include the full commercial rights for the use of CRISPR edited cell lines for the Good Manufacturing Practice (GMP) manufacturing of biotherapeutics. The Company has also entered into a grant-funded collaboration with Solentim, the developer of the Cell MetricTM and dedicated instrumentation for cell line development, to establish automated approaches for the gene editing of cell lines.
With this license amendment, Horizon now adds the right to use CRISPR edited cell lines in GMP biomanufacturing. This extends Horizon’s coverage for CRISPR to include virtually all non-therapeutic applications, strengthening its core capabilities and keeping the Company at the forefront of gene editing. Further, through the recently signed global agreement between ...
